48,455
edits
Difference between revisions of "Urothelial carcinoma"
Jump to navigation
Jump to search
→UCC versus other
| Line 120: | Line 120: | ||
:''See [[urothelial carcinoma in situ]]''. | :''See [[urothelial carcinoma in situ]]''. | ||
===UCC versus other=== | ===UCC versus other cancers=== | ||
UCC vs. [[Prostate cancer|prostate]]: | UCC vs. [[Prostate cancer|prostate]]: | ||
*UCC: GATA3 +ve, PSA -ve, [[p63]] +ve, [[CK20]] +ve. | *UCC: GATA3 +ve, PSA -ve, [[p63]] +ve, [[CK20]] +ve. | ||
*Prostate: [[PSA]] +ve, [[GATA3]] -ve, [[PSAP]] +ve, CK7 -ve, CK20 -ve, p63 -ve. | *Prostate: [[PSA]] +ve, [[GATA3]] -ve, [[PSAP]] +ve, CK7 -ve, CK20 -ve, p63 -ve. | ||
UCC vs. [[renal cell carcinoma| | UCC vs. [[renal cell carcinoma|renal cell carcinoma]]: | ||
*UCC: p63 +ve.<ref>{{Cite journal | last1 = Langner | first1 = C. | last2 = Ratschek | first2 = M. | last3 = Tsybrovskyy | first3 = O. | last4 = Schips | first4 = L. | last5 = Zigeuner | first5 = R. | title = P63 immunoreactivity distinguishes upper urinary tract transitional-cell carcinoma and renal-cell carcinoma even in poorly differentiated tumors. | journal = J Histochem Cytochem | volume = 51 | issue = 8 | pages = 1097-9 | month = Aug | year = 2003 | doi = | PMID = 12871991 }} | *UCC: p63 +ve.<ref>{{Cite journal | last1 = Langner | first1 = C. | last2 = Ratschek | first2 = M. | last3 = Tsybrovskyy | first3 = O. | last4 = Schips | first4 = L. | last5 = Zigeuner | first5 = R. | title = P63 immunoreactivity distinguishes upper urinary tract transitional-cell carcinoma and renal-cell carcinoma even in poorly differentiated tumors. | journal = J Histochem Cytochem | volume = 51 | issue = 8 | pages = 1097-9 | month = Aug | year = 2003 | doi = | PMID = 12871991 }} | ||
</ref> | </ref> | ||
Metastatic UCC versus primary lung | Metastatic UCC versus primary lung squamous cell carcinoma: | ||
:See ''[[Squamous_cell_carcinoma_of_the_lung#Lung_SCC_versus_metastatic_bladder_urothelial_carcinoma]]''. | |||
Note: | Note: | ||